Select your country
Select a country to go to the website of the respective STADA sales company.
Czech Republic (1)
United Kingdom (4)
Xbrane Biopharma AB (“Xbrane”) and STADA Arzneimittel AG (“STADA”) have entered into a co-development agreement for Xlucane, a Lucentis® (ra…
STADA continues to advance its strategic reorientation.
STADA has today published the solicitation to the noteholders of the STADA Euro bond 2015/2022.
STADA Arzneimittel AG announced today that the Company’s shareholders approved all agenda items with a large majority that were put to a vot…
STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange
STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of…
CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a d…
The Extraordinary General Meeting of STADA Arzneimittel AG (STADA) on February 2, 2018 with a majority of 99 percent approved the conclusion…
The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2…
STADA is advancing the internationalization of its OTC brand business.